Skip to main content

Table 5 Univariate and multivariate overall survival analysis of different prognostic variables and Parkin methylation in breast cancer patients by cox proportional hazard model

From: Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients

Variables Univariate analysis Multivariate analysis
Hazard ratio 95% CI P Value Hazard ratio 95% CI P Value
Age (< 50 yr. vs. ≥50 yr.) 1.535 0.688–3.422 0.295
Weight (< 60 kg vs. ≥60 kg) 0.720 0.408–1.270 0.295
Tumour size (< 4 cm vs. ≥4 cm) 1.322 0.745–2.347 0.340
Clinical Stage (I + II vs. III + IV) 1.409 1.028–1.930 0.033* 1.541 1.139–2.083 0.005*
Histologicala grade (WD vs. MD + PD) 3.659 1.641–8.162 0.002* 3.316 1.462–7.524 0.004*
Lymph Node (Neg. vs. Pos.) 3.427 1.812–6.483 < 0.0001* 2.769 1.453–5.277 0.002*
Menopause (Pre vs. Post) 2.184 0.979–.4.870 0.056
ERb (Neg. vs. Pos.) 0.843 0.476–1.491 0.557
PRc (Neg. vs. Pos.) 0.717 0.380–1.356 0.306
Her-2d (Neg. vs. Pos.) 1.784 0.999–3.184 0.050
TNBCe (No vs. Yes) 0.839 0.450–1.563 0.579
Methylation (Meth. vs. Unmeth.) 2.892 1.528–5.474 0.001* 2.286 1.190–4.389 0.013*
  1. a WD Well differentiated, MD Moderately differentiated, PD Poorly differentiated
  2. b Estrogen receptor
  3. c Progesterone receptor
  4. d human epidermal growth factor receptor 2
  5. e Triple Negative breast cancer, *Significant Correlation (P < 0.05)